Vigabatrin Criteria

Revised: 11/01/2026

VIGABATRIN CRITERIA

Length of Authorization: 1 year

CHILDREN – CRITERIA TO APPROVE

All the following:

- **One** of the following:
  - The patient is ≥ 2 years of age with a diagnosis of refractory complex partial seizures as adjunctive therapy; **OR**
  - The patient is ≥ 1 month of age to < 2 years of age with a diagnosis of infantile spasms; **AND**
- The prescriber is a neurologist or consult notes from a neurology office are provided.

ADULTS – CRITERIA TO APPROVE

All the following:

- The patient is ≥ 18 years of age
- The patient received a diagnosis of refractory complex partial seizures as adjunctive therapy
- The prescriber is a neurologist or consult notes from a neurology office are provided.

ADULTS – RENEWAL CRITERIA

All the following:

- The patient is responding well to therapy.
- The patient has not experienced any treatment-restricting adverse effects.

All brand names are property of their respective owners.
© 2024–2026 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

REVISION HISTORY

Date	Issues/Updates
11/01/2026	• Criteria updated to remove Sabril powder packet. Criteria will be used for all generic vigabatrin formulations.
07/01/2025	• Criteria updated to reflect Sabril powder packet and Vigabatrin tablet as preferred. No clinical updates
07/10/2024	• Initial draft creation

© 2024–2026 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company